De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Enovis Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Enovis is gedaald met een gemiddeld jaarlijks percentage van -48%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 11.5%. De inkomsten zijn daalde met een gemiddeld percentage van 15.7% per jaar.

Belangrijke informatie

-48.0%

Groei van de winst

-46.9%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	-15.7%
Rendement op eigen vermogen	-3.2%
Nettomarge	-5.6%
Laatste winstupdate	28 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Enovis geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NYSE:ENOV Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
28 Jun 24	1,914	-107	897	85
29 Mar 24	1,817	-103	841	81
31 Dec 23	1,707	-54	792	75
29 Sep 23	1,661	-112	789	72
30 Jun 23	1,627	-159	769	67
31 Mar 23	1,594	-23	742	64
31 Dec 22	1,563	-39	712	61
30 Sep 22	1,553	1	701	61
01 Jul 22	1,530	54	626	58
01 Apr 22	1,491	-109	639	54
31 Dec 21	1,426	-103	642	49
01 Oct 21	1,855	-48	524	102
02 Jul 21	2,301	-18	701	90
02 Apr 21	2,565	21	759	60
31 Dec 20	1,121	-75	511	34
02 Oct 20	3,131	53	886	62
03 Jul 20	3,172	39	898	62
03 Apr 20	3,460	42	952	80
31 Dec 19	3,327	8	873	62
27 Sep 19	3,014	10	843	34
28 Jun 19	2,692	21	682	34
29 Mar 19	2,344	66	513	34
31 Dec 18	2,193	108	463	34
28 Sep 18	2,492	-115	492	43
29 Jun 18	2,813	-84	544	43
30 Mar 18	3,100	-92	585	43
31 Dec 17	1,937	28	425	33
29 Sep 17	3,239	154	612	39
30 Jun 17	3,161	147	598	39
31 Mar 17	3,043	151	566	39
31 Dec 16	3,186	138	606	39
30 Sep 16	3,435	144	643	42
01 Jul 16	3,637	126	712	42
01 Apr 16	3,933	138	790	42
31 Dec 15	3,434	158	657	38
25 Sep 15	4,112	204	814	43
26 Jun 15	4,307	259	822	43
27 Mar 15	4,481	397	860	43
31 Dec 14	4,624	370	878	43
26 Sep 14	4,589	322	884	27
27 Jun 14	4,440	299	847	27
28 Mar 14	4,314	160	808	27
31 Dec 13	4,207	154	791	27

Kwaliteitswinsten: ENOV is momenteel verliesgevend.

Groeiende winstmarge: ENOV is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ENOV is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 48% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van ENOV over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: ENOV is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 7.9% ).

Rendement op eigen vermogen

Hoge ROE: ENOV heeft een negatief Return on Equity ( -3.24% ), omdat het momenteel verliesgevend is.

Enovis Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS misses analyst expectations

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Price target decreased by 7.1% to US$67.00

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of Emowr Revision Knee

It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Enovis Corporation Introduces Star Ankle, Now with E+ Polyethylene for Unmatched Durability

Consensus EPS estimates fall by 20%

Second quarter 2024 earnings: EPS misses analyst expectations

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

Enovis Languishing Despite Respectable Performance

Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated with AltiVate Reverse

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis: Solid Growth, But Unstable Financial Footing

Enovis Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Price target increased by 8.6% to US$75.20

Full year 2023 earnings: EPS exceeds analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2024

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Is Enovis (NYSE:ENOV) Using Too Much Debt?

Investors Holding Back On Enovis Corporation (NYSE:ENOV)

Enovis Corporation Announces Leadership Transition Plan

Consensus EPS estimates fall by 87%

No longer forecast to breakeven

Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Making Good Choices, But Not Seeing The Rewards

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Is Enovis (NYSE:ENOV) A Risky Investment?

New major risk - Revenue and earnings growth

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

Price target increased by 8.0% to US$68.17

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

Forecast breakeven date pushed back to 2024

We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Independent Director notifies of intention to sell stock

Enovis Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS misses analyst expectations

Enovis Corporation Q4 2022 Earnings Preview

Is Enovis (NYSE:ENOV) A Risky Investment?

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2022

Enovis Corporation reports Q3 earnings beat; updates FY22 guidance

Is Enovis (NYSE:ENOV) A Risky Investment?

Now 21% undervalued after recent price drop

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?

Price target decreased to US$67.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Enovis Launches ARVIS®, Only Augmented Reality Surgical Guidance System Designed Specifically to Improve Both Total Hip and Knee Replacement Surgery

Enovis launches augmented reality system ARVIS for use in hip, knee surgery